nafamostat has been researched along with Disseminated Intravascular Coagulation in 34 studies
nafamostat: inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplastic
Disseminated Intravascular Coagulation: A disorder characterized by procoagulant substances entering the general circulation causing a systemic thrombotic process. The activation of the clotting mechanism may arise from any of a number of disorders. A majority of the patients manifest skin lesions, sometimes leading to PURPURA FULMINANS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "After 9 years of treatment for Parkinson's disease, a 68-year-old woman developed the complications of neuroleptic malignant syndrome (NMS) and disseminated intravascular coagulation (DIC) while she was still receiving levodopa, bromocriptine and amantadine hydrochloride." | 8.78 | Successful treatment of levodopa-induced neuroleptic malignant syndrome (NMS) and disseminated intravascular coagulation (DIC) in a patient with Parkinson's disease. ( Ogawa, N; Yamawaki, Y, 1992) |
| "Nafamostat, a serine proteinase inhibitor with various actions including antithrombin, antiplasmin, and antitrypsin effects, has been used in clinical practice to treat disseminated intravascular coagulation (DIC) and pancreatitis." | 8.02 | Potential mechanisms of nafamostat therapy for severe COVID-19 pneumonia with disseminated intravascular coagulation. ( Asakura, H; Koba, H; Ogawa, H; Takahashi, W; Tsuji, N; Ueda, T; Yoneda, T, 2021) |
| "We evaluated clinical outcomes of disseminated intravascular coagulation (DIC) in patients with hematological malignancies treated with synthetic protease inhibitors (SPIs) and compared the effects of gabexate mesilate (FOY) and nafamostat mesilate (FUT)." | 7.91 | Comparison of gabexate mesilate and nafamostat mesilate for disseminated intravascular coagulation associated with hematological malignancies. ( Ashizawa, M; Fujiwara, SI; Hatano, K; Ikeda, T; Ito, S; Kanda, Y; Kawaguchi, SI; Kawasaki, Y; Mashima, K; Minakata, D; Morita, K; Muroi, K; Nagayama, T; Nakano, H; Ochi, SI; Oh, I; Ohmine, K; Ohmori, T; Sato, K; Sugimoto, M; Toda, Y; Umino, K; Yamamoto, C; Yamasaki, R, 2019) |
| "Effects of dermatan sulfate (DS) on the endotoxin-induced disseminated intravascular coagulation (DIC) rat model were compared with those of low-molecular weight heparin (LMWH), nafamostat mesilate (NM) and argathroban (AR)." | 7.70 | Effects of dermatan sulfate, a heparin cofactor II mediated thrombin inhibitor, on the endotoxin-induced disseminated intravascular coagulation model in the rat: comparison with low-molecular weight heparin, nafamostat mesilate and argathroban. ( Horie, K; Kyogashima, M; Miyauchi, S; Mizuno, S; Onaya, J; Sunose, A, 1998) |
| "FUT has been reported as a drug for the treatments of DIC (disseminated intravascular coagulation) and acute pancreatitis and as an anticoagulant in extracorporeal circulation." | 6.41 | [Pharmacokinetics studies of nafamostat mesilate (FUT), a synthetic protease inhibitor, which has been used for the treatments of DIC and acute pancreatitis, and as an anticoagulant in extracorporeal circulation]. ( Tsukagoshi, S, 2000) |
| "Dantrolene was effective on the elevated COK level and FUT-175 was effective on the DIC, and symptoms of NMS and DIC were completely improved after a period of 14 days." | 6.38 | [Successful treatment of levodopa-induced neuroleptic malignant syndrome (NMS) with disseminated intravascular coagulation (DIC) in a patient with Parkinson's disease]. ( Ogawa, N; Yamawaki, Y, 1991) |
| "A 65-year-old man with chronic aortic dissection experienced two massive subcutaneous hemorrhages." | 5.35 | Effects of nafamostat mesilate on coagulopathy with chronic aortic dissection. ( Hiraiwa, T; Ito, H; Tanaka, K; Yamamoto, K, 2009) |
| "Nafamostat mesilate was considered effective for HANE attack." | 5.28 | [Hereditary angioneurotic edema associated with DIC and treated effectively by nafamostat mesilate]. ( Kayashima, S; Kimura, F; Makishima, M; Matuura, Y; Mineshita, M; Sasaki, T; Satou, N; Shimomura, S; Takagi, S; Yamamoto, K, 1992) |
| "After 9 years of treatment for Parkinson's disease, a 68-year-old woman developed the complications of neuroleptic malignant syndrome (NMS) and disseminated intravascular coagulation (DIC) while she was still receiving levodopa, bromocriptine and amantadine hydrochloride." | 4.78 | Successful treatment of levodopa-induced neuroleptic malignant syndrome (NMS) and disseminated intravascular coagulation (DIC) in a patient with Parkinson's disease. ( Ogawa, N; Yamawaki, Y, 1992) |
| "Nafamostat, a serine proteinase inhibitor with various actions including antithrombin, antiplasmin, and antitrypsin effects, has been used in clinical practice to treat disseminated intravascular coagulation (DIC) and pancreatitis." | 4.02 | Potential mechanisms of nafamostat therapy for severe COVID-19 pneumonia with disseminated intravascular coagulation. ( Asakura, H; Koba, H; Ogawa, H; Takahashi, W; Tsuji, N; Ueda, T; Yoneda, T, 2021) |
| "We evaluated clinical outcomes of disseminated intravascular coagulation (DIC) in patients with hematological malignancies treated with synthetic protease inhibitors (SPIs) and compared the effects of gabexate mesilate (FOY) and nafamostat mesilate (FUT)." | 3.91 | Comparison of gabexate mesilate and nafamostat mesilate for disseminated intravascular coagulation associated with hematological malignancies. ( Ashizawa, M; Fujiwara, SI; Hatano, K; Ikeda, T; Ito, S; Kanda, Y; Kawaguchi, SI; Kawasaki, Y; Mashima, K; Minakata, D; Morita, K; Muroi, K; Nagayama, T; Nakano, H; Ochi, SI; Oh, I; Ohmine, K; Ohmori, T; Sato, K; Sugimoto, M; Toda, Y; Umino, K; Yamamoto, C; Yamasaki, R, 2019) |
| "Effects of dermatan sulfate (DS) on the endotoxin-induced disseminated intravascular coagulation (DIC) rat model were compared with those of low-molecular weight heparin (LMWH), nafamostat mesilate (NM) and argathroban (AR)." | 3.70 | Effects of dermatan sulfate, a heparin cofactor II mediated thrombin inhibitor, on the endotoxin-induced disseminated intravascular coagulation model in the rat: comparison with low-molecular weight heparin, nafamostat mesilate and argathroban. ( Horie, K; Kyogashima, M; Miyauchi, S; Mizuno, S; Onaya, J; Sunose, A, 1998) |
| "Nafamostat mesilate (NM), a synthetic protease inhibitor, is frequently used for the treatment of disseminated intravascular coagulation (DIC) in Japan." | 3.69 | Effect of nafamostat mesilate, a synthetic protease inhibitor, on tissue factor-factor VIIa complex activity. ( Abe, H; Okabe, H; Okajima, K; Takatsuki, K; Uchiba, M, 1994) |
| "The pathology of coronavirus disease 2019 (COVID-19) is exacerbated by the progression of thrombosis, and disseminated intravascular coagulation (DIC), and cytokine storms." | 2.72 | COVID-19-associated coagulopathy and disseminated intravascular coagulation. ( Asakura, H; Ogawa, H, 2021) |
| "Whereas in DIC associated with trauma, since balance between coagulation and fibrinolysis collapses drastically in a short period, both anticoagulantion therapy and antifibrinolytic therapy can be utilized depending on clinical conditions." | 2.53 | [Anti DIC therapy]. ( Sakamoto, Y; Yahata, M, 2016) |
| "FUT has been reported as a drug for the treatments of DIC (disseminated intravascular coagulation) and acute pancreatitis and as an anticoagulant in extracorporeal circulation." | 2.41 | [Pharmacokinetics studies of nafamostat mesilate (FUT), a synthetic protease inhibitor, which has been used for the treatments of DIC and acute pancreatitis, and as an anticoagulant in extracorporeal circulation]. ( Tsukagoshi, S, 2000) |
| "5 days later he developed adult respiratory distress syndrome (ARDS)." | 2.39 | [A case of adult onset Still's disease complicated with adult respiratory distress syndrome and disseminated intravascular coagulation]. ( Akizuki, M; Fujii, T; Ichikawa, Y; Mimori, T; Shinozawa, T; Suwa, A; Tojo, T; Yokoyama, M, 1995) |
| "Dantrolene was effective on the elevated COK level and FUT-175 was effective on the DIC, and symptoms of NMS and DIC were completely improved after a period of 14 days." | 2.38 | [Successful treatment of levodopa-induced neuroleptic malignant syndrome (NMS) with disseminated intravascular coagulation (DIC) in a patient with Parkinson's disease]. ( Ogawa, N; Yamawaki, Y, 1991) |
| "She developed disseminated intravascular coagulation on the fourth day after admission." | 1.40 | Adult-onset Still's disease with disseminated intravascular coagulation and hemophagocytic syndrome: a case report. ( Kibata, M; Mimura, T; Shimodaira, M; Shirahata, K; Tsukadaira, A, 2014) |
| "A 65-year-old man with chronic aortic dissection experienced two massive subcutaneous hemorrhages." | 1.35 | Effects of nafamostat mesilate on coagulopathy with chronic aortic dissection. ( Hiraiwa, T; Ito, H; Tanaka, K; Yamamoto, K, 2009) |
| "Nafamostat mesilate was considered effective for HANE attack." | 1.28 | [Hereditary angioneurotic edema associated with DIC and treated effectively by nafamostat mesilate]. ( Kayashima, S; Kimura, F; Makishima, M; Matuura, Y; Mineshita, M; Sasaki, T; Satou, N; Shimomura, S; Takagi, S; Yamamoto, K, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (14.71) | 18.7374 |
| 1990's | 14 (41.18) | 18.2507 |
| 2000's | 3 (8.82) | 29.6817 |
| 2010's | 10 (29.41) | 24.3611 |
| 2020's | 2 (5.88) | 2.80 |
| Authors | Studies |
|---|---|
| Takahashi, W | 1 |
| Yoneda, T | 1 |
| Koba, H | 1 |
| Ueda, T | 1 |
| Tsuji, N | 1 |
| Ogawa, H | 2 |
| Asakura, H | 2 |
| Minakata, D | 1 |
| Fujiwara, SI | 1 |
| Ikeda, T | 1 |
| Kawaguchi, SI | 1 |
| Toda, Y | 1 |
| Ito, S | 1 |
| Ochi, SI | 1 |
| Nagayama, T | 1 |
| Mashima, K | 1 |
| Umino, K | 1 |
| Nakano, H | 1 |
| Yamasaki, R | 1 |
| Morita, K | 1 |
| Kawasaki, Y | 1 |
| Sugimoto, M | 1 |
| Yamamoto, C | 1 |
| Ashizawa, M | 1 |
| Hatano, K | 1 |
| Sato, K | 1 |
| Oh, I | 1 |
| Ohmine, K | 1 |
| Muroi, K | 1 |
| Ohmori, T | 1 |
| Kanda, Y | 1 |
| Wada, H | 1 |
| Matsumoto, T | 1 |
| Yamashita, Y | 1 |
| Mimura, T | 1 |
| Shimodaira, M | 1 |
| Kibata, M | 1 |
| Tsukadaira, A | 1 |
| Shirahata, K | 1 |
| Machioka, K | 1 |
| Shigehara, K | 1 |
| Kadomoto, S | 1 |
| Iwamoto, H | 1 |
| Miyagi, T | 1 |
| Nakashima, T | 1 |
| Namiki, M | 1 |
| Nishimura, H | 1 |
| Yamaya, M | 1 |
| Kawano, H | 1 |
| Hata, T | 1 |
| Uda, A | 1 |
| Maemura, K | 1 |
| Goto, S | 1 |
| Ookawara, S | 1 |
| Tabei, K | 1 |
| Yahata, M | 1 |
| Sakamoto, Y | 1 |
| Yamamoto, K | 2 |
| Ito, H | 1 |
| Hiraiwa, T | 1 |
| Tanaka, K | 1 |
| Koyama, T | 1 |
| Takahashi, H | 1 |
| Yoshikawa, T | 2 |
| Murakami, M | 2 |
| Furukawa, Y | 2 |
| Onodera, H | 1 |
| Yoshida, N | 1 |
| Ueda, M | 1 |
| Kato, H | 2 |
| Takemura, S | 2 |
| Sugino, S | 1 |
| Kondo, M | 2 |
| Denno, R | 1 |
| Hasegawa, I | 1 |
| Sasaki, K | 1 |
| Gotoh, Y | 1 |
| Ebata, T | 1 |
| Totsuka, M | 1 |
| Hayasaka, H | 1 |
| Yokoyama, M | 1 |
| Suwa, A | 1 |
| Shinozawa, T | 1 |
| Fujii, T | 1 |
| Mimori, T | 1 |
| Akizuki, M | 1 |
| Ichikawa, Y | 1 |
| Tojo, T | 1 |
| Ohsawa, T | 1 |
| Tsubota, M | 1 |
| Endo, M | 1 |
| Kobayashi, K | 1 |
| Sato, H | 1 |
| Seki, M | 1 |
| Uchiba, M | 1 |
| Okajima, K | 1 |
| Abe, H | 1 |
| Okabe, H | 1 |
| Takatsuki, K | 1 |
| Aramoto, H | 1 |
| Saito, H | 1 |
| Shigematsu, H | 1 |
| Muto, T | 1 |
| Suzuki, H | 1 |
| Nimura, Y | 1 |
| Kamiya, J | 1 |
| Kondo, S | 1 |
| Nagino, M | 1 |
| Kanai, M | 1 |
| Miyachi, M | 1 |
| Onaya, J | 1 |
| Kyogashima, M | 1 |
| Sunose, A | 1 |
| Miyauchi, S | 1 |
| Mizuno, S | 1 |
| Horie, K | 1 |
| Tsukagoshi, S | 2 |
| Kashima, K | 1 |
| Kataoka, K | 1 |
| Umehara, K | 1 |
| Yamawaki, Y | 2 |
| Ogawa, N | 2 |
| Mineshita, M | 1 |
| Kayashima, S | 1 |
| Makishima, M | 1 |
| Kimura, F | 1 |
| Sasaki, T | 1 |
| Takagi, S | 1 |
| Matuura, Y | 1 |
| Shimomura, S | 1 |
| Satou, N | 1 |
| Murakawa, M | 1 |
| Okamura, T | 1 |
| Shibuya, T | 1 |
| Harada, M | 1 |
| Otsuka, T | 1 |
| Niho, Y | 1 |
| Yoshida, K | 1 |
| Toki, F | 1 |
| Takeuchi, T | 1 |
| Kuroda, T | 1 |
| Suzuki, S | 1 |
| Konno, M | 1 |
| Amano, T | 1 |
| Mikame, M | 1 |
| Okamoto, K | 1 |
| Takeda, S | 1 |
| Ohsato, K | 1 |
| Takemoto, Y | 1 |
| Tanaka, S | 1 |
| Tanabe, J | 1 |
| Nakamura, Y | 1 |
| Kohama, A | 1 |
| Shibata, S | 1 |
| Koshiyama, Y | 1 |
| Kobori, A | 1 |
| Ogihara, M | 1 |
| Yokomoto, Y | 1 |
| Ohtani, K | 1 |
| Shimamura, K | 1 |
| Iwaki, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| RAndomized Clinical Trial in COvid19 Patients to Assess the Efficacy of the Transmembrane Protease Serine 2 (TMPRSS2) Inhibitor NAfamostat (RACONA Study)[NCT04352400] | Phase 2/Phase 3 | 256 participants (Anticipated) | Interventional | 2021-06-04 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
12 reviews available for nafamostat and Disseminated Intravascular Coagulation
| Article | Year |
|---|---|
COVID-19-associated coagulopathy and disseminated intravascular coagulation.
Topics: Adult; Anticoagulants; Benzamidines; Blood Coagulation Disorders; Blood Coagulation Tests; COVID-19; | 2021 |
[Recent therapeutic strategy for disseminated intravascular coagulation].
Topics: Anticoagulants; Antifibrinolytic Agents; Antithrombins; Benzamidines; Disseminated Intravascular Coa | 2014 |
[Anti DIC therapy].
Topics: Anticoagulants; Antifibrinolytic Agents; Antithrombins; Benzamidines; Disseminated Intravascular Coa | 2016 |
[Treatment of disseminated intravascular coagulation].
Topics: Anticoagulants; Antithrombins; Benzamidines; Chondroitin Sulfates; Dalteparin; Dermatan Sulfate; Dis | 2010 |
[Synthetic protease inhibitors for the treatment of DIC].
Topics: Anticoagulants; Arginine; Benzamidines; Disseminated Intravascular Coagulation; Gabexate; Guanidines | 2011 |
[A case of adult onset Still's disease complicated with adult respiratory distress syndrome and disseminated intravascular coagulation].
Topics: Aged; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Benzamidines; Disseminated | 1995 |
[Synthetic protease inhibitors in the treatment of disseminated intravascular coagulation].
Topics: Benzamidines; Disseminated Intravascular Coagulation; Gabexate; Glycoproteins; Guanidines; Half-Life | 1993 |
Preoperative transcatheter arterial embolization for giant cavernous hemangioma of the liver with consumption coagulopathy.
Topics: Adult; Anticoagulants; Benzamidines; Combined Modality Therapy; Disseminated Intravascular Coagulati | 1997 |
[Pharmacokinetics studies of nafamostat mesilate (FUT), a synthetic protease inhibitor, which has been used for the treatments of DIC and acute pancreatitis, and as an anticoagulant in extracorporeal circulation].
Topics: Acute Disease; Adult; Anticoagulants; Benzamidines; Disseminated Intravascular Coagulation; Extracor | 2000 |
[Molecular specificity of nafamostat mesilate (FUT), a drug used for the treatments of DIC and acute pancreatitis and as an anticoagulant--the pharmacodynamics and pharmacological action].
Topics: Benzamidines; Disseminated Intravascular Coagulation; Guanidines; Humans; Inhibitory Concentration 5 | 2001 |
Successful treatment of levodopa-induced neuroleptic malignant syndrome (NMS) and disseminated intravascular coagulation (DIC) in a patient with Parkinson's disease.
Topics: Aged; Antithrombins; Benzamidines; Dantrolene; Disseminated Intravascular Coagulation; Female; Guani | 1992 |
[Successful treatment of levodopa-induced neuroleptic malignant syndrome (NMS) with disseminated intravascular coagulation (DIC) in a patient with Parkinson's disease].
Topics: Aged; Benzamidines; Dantrolene; Disseminated Intravascular Coagulation; Female; Guanidines; Humans; | 1991 |
22 other studies available for nafamostat and Disseminated Intravascular Coagulation
| Article | Year |
|---|---|
Potential mechanisms of nafamostat therapy for severe COVID-19 pneumonia with disseminated intravascular coagulation.
Topics: Aged; Anticoagulants; Benzamidines; Blood Coagulation; COVID-19; Disseminated Intravascular Coagulat | 2021 |
Comparison of gabexate mesilate and nafamostat mesilate for disseminated intravascular coagulation associated with hematological malignancies.
Topics: Adult; Anticoagulants; Benzamidines; Disseminated Intravascular Coagulation; Female; Gabexate; Guani | 2019 |
Adult-onset Still's disease with disseminated intravascular coagulation and hemophagocytic syndrome: a case report.
Topics: Anti-Inflammatory Agents; Benzamidines; Disseminated Intravascular Coagulation; Female; Guanidines; | 2014 |
[Treatment with recombinant thrombomodulin on disseminated intravascular coagulation caused by urinary tract infections; a retrospective comparative study with control cases].
Topics: Aged; Aged, 80 and over; Anticoagulants; Benzamidines; Disseminated Intravascular Coagulation; Femal | 2015 |
A Synthetic Serine Protease Inhibitor, Nafamostat Mesilate, Is a Drug Potentially Applicable to the Treatment of Ebola Virus Disease.
Topics: Animals; Antiviral Agents; Benzamidines; Disseminated Intravascular Coagulation; Ebolavirus; Factor | 2015 |
Use of rivaroxaban for the effective management of disseminated intravascular coagulation associated with abdominal aortic aneurysm.
Topics: Aged; Anticoagulants; Aortic Aneurysm, Abdominal; Benzamidines; Blood Platelets; Blood Transfusion; | 2015 |
Effectiveness of Plasma Exchange for Acute Pancreatitis Induced by Hypertriglyceridemia During Pregnancy.
Topics: Adult; Anticoagulants; Benzamidines; Disseminated Intravascular Coagulation; Female; Guanidines; Hum | 2016 |
Effects of nafamostat mesilate on coagulopathy with chronic aortic dissection.
Topics: Aged; Aortic Aneurysm, Thoracic; Aortic Dissection; Benzamidines; Blood Vessel Prosthesis Implantati | 2009 |
[Inhibition of platelet aggregation and prevention of endotoxin-induced DIC by a protease inhibitor, FUT-175, in rats].
Topics: Animals; Benzamidines; Disseminated Intravascular Coagulation; Female; Guanidines; Humans; Platelet | 1984 |
Effects of FUT-175, a new synthetic protease inhibitor on endotoxin-induced disseminated intravascular coagulation in rats.
Topics: Animals; Benzamidines; Disseminated Intravascular Coagulation; Endotoxins; Female; Fibrin Fibrinogen | 1983 |
[Effects of new protease inhibitor (FUT-175) on experimental DIC].
Topics: Animals; Benzamidines; Blood Pressure; Disseminated Intravascular Coagulation; Endotoxins; Guanidine | 1984 |
[A successfully treated case of thoracoabdominal aortic aneurysm complicated with the coagulation disorder].
Topics: Aged; Anticoagulants; Antithrombins; Aortic Aneurysm, Abdominal; Aortic Aneurysm, Thoracic; Benzamid | 1995 |
Effect of nafamostat mesilate, a synthetic protease inhibitor, on tissue factor-factor VIIa complex activity.
Topics: Amino Acid Sequence; Benzamidines; Blood Coagulation; Disseminated Intravascular Coagulation; Factor | 1994 |
Effects of dermatan sulfate, a heparin cofactor II mediated thrombin inhibitor, on the endotoxin-induced disseminated intravascular coagulation model in the rat: comparison with low-molecular weight heparin, nafamostat mesilate and argathroban.
Topics: Animals; Arginine; Benzamidines; Dermatan Sulfate; Disease Models, Animal; Disseminated Intravascula | 1998 |
[Treatment of acute pancreatitis].
Topics: Acute Disease; Benzamidines; Disseminated Intravascular Coagulation; Drainage; Gabexate; Glycoprotei | 1992 |
[Hereditary angioneurotic edema associated with DIC and treated effectively by nafamostat mesilate].
Topics: Adult; Angioedema; Benzamidines; Complement C1 Inactivator Proteins; Disseminated Intravascular Coag | 1992 |
Use of a synthetic protease inhibitor for the treatment of L-asparaginase-induced acute pancreatitis complicated by disseminated intravascular coagulation.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Benz | 1992 |
[Antienzyme preparations in the treatment of acute pancreatitis].
Topics: Acute Disease; Adult; Aprotinin; Benzamidines; Cytidine Diphosphate Choline; Disseminated Intravascu | 1990 |
[A case of scrub typhus with disseminated intravascular coagulation, meningitis and pulmonary fibrosis].
Topics: Benzamidines; Disseminated Intravascular Coagulation; Guanidines; Humans; Hydrocortisone; Male; Meni | 1991 |
[Treatment of disseminated intravascular coagulation with proteinase inhibitor].
Topics: Antithrombin III; Benzamidines; Disseminated Intravascular Coagulation; Drug Therapy, Combination; F | 1991 |
Studies on the effects of primary therapy for DIC following circulatory arrest.
Topics: Animals; Anticoagulants; Benzamidines; Blood Coagulation Tests; Disseminated Intravascular Coagulati | 1986 |
[The effects of FUT-175 (nafamostat mesilate) on blood coagulation and experimental disseminated intravascular coagulation (DIC)].
Topics: Animals; Benzamidines; Blood Coagulation; Disseminated Intravascular Coagulation; Guanidines; Male; | 1987 |